- Submitted application to Health Canada for license that will allow in-house research in new facility
- Appointed Dr. Ed Ergenzinger to executive team as chief legal officer and senior VP of innovation
- Recruiting new staff, expanding work schedules and reducing costs and development timelines
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a biotech company and drug delivery platform innovator, announced in a recent press release (http://ibn.fm/40WPx) that it has submitted a Health Canada research application and has appointed a new member to its executive team.
The research application has been submitted for the operation of a Kelowna-based research and development laboratory to work with cannabinoids. The lab will be located within Lexaria’s new head office. The office and lab are presently under construction in Canada, and completion is expected by the end of January 2019.
Having the work done in-house will help expand the work schedule and reduce costs and development timelines. The company is currently recruiting new staff as it prepares for an increase in operations. Once the research license has been approved under Health Canada’s Cannabis Tracking and Licensing System, Lexaria expects to begin work on cannabinoid-related formulations. There are also plans in place to begin experimental work on nicotine formulations, nonsteroidal anti-inflammatory drugs, vitamins and other bioactive compounds.
Lexaria has appointed Ed Ergenzinger as its new chief legal officer and senior vice president of innovation. Ergenzinger brings to the company over 15 years of experience providing patent services. He is a published author of over 40 scientific and legal publications, a U.S. licensed patent attorney with a doctorate in neuroscience and an adjunct professor of law. He is serving as an outside patent counsel to Lexaria.
A global leader in the delivery enhancement of orally-administered products, Lexaria has conducted ground-breaking studies that have opened doors previously closed to disruptive new delivery technology. The company has four wholly owned subsidiaries that have global exclusive licenses to utilize and sub-license DehydraTECH, a complimentary edible technology, for the delivery of molecules within their respective industries (nicotine, pharmaceuticals, hemp and other). Lexaria does not seek to compete with but rather to enhance existing and new products from third-party partners. DehydraTECH is currently patented or patent-pending in over 40 countries and has applications across a wide range of ingestible products.
For more information, visit the company’s website at www.LexariaBioscience.com